RxDoctor Payments Data

William Lacorte

Geriatric Medicine · Metairie, LANPI 1619065497

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 53 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 22 manufacturers, the largest accounting for just 13.4% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $640 and has fallen 81.9% since, to $116 in 2023. Among geriatric medicine clinicians in LA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$1,318in general payments, 2019–2025

Across 53 payments — averaging $24.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$177
  • E.r. Squibb & Sons, L.L.C.$133
  • Urovant Sciences Inc$130
  • Avanir Pharmaceuticals, Inc.$129
  • Sunovion Pharmaceuticals Inc.$125
  • Cardinal Health 200 LLC$114
  • plus $510 from 16 others

What the payments were for

  • Food & beverage$1,318100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,318 in reported general payments places this provider in the 90th percentile of 40 geriatric medicine providers in Louisiana.

See all geriatric medicine providers in Louisiana

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban226$84,881
JanuviaSitagliptin Phosphate95$40,265
JardianceEmpagliflozin24$9,422
Potassium Chloride164$6,729
MyrbetriqMirabegron19$5,395
TradjentaLinagliptin14$4,743
Levetiracetam75$4,019
Atorvastatin Calcium267$3,132
Pantoprazole Sodium113$2,815
Olanzapine114$2,733
Lidocaine14$2,381
Megestrol Acetate35$1,717
Quetiapine Fumarate90$1,624
Escitalopram Oxalate127$1,602
Tamsulosin Hcl80$1,499

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCOlanzapine$177$2,733114 claims
Novo NordiskNovolog$30$1,13811 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 40 geriatric medicine providers in Louisiana.

Other geriatric medicine in Metairie

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →